These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25398397)

  • 1. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
    [No Abstract]   [Full Text] [Related]  

  • 3. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
    Menderes G; Bonazzoli E; Bellone S; Altwerger G; Black JD; Dugan K; Pettinella F; Masserdotti A; Riccio F; Bianchi A; Zammataro L; de Haydu C; Buza N; Hui P; Wong S; Huang GS; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Oct; 147(1):145-152. PubMed ID: 28705408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
    Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR
    Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
    Montero JC; García-Alonso S; Ocaña A; Pandiella A
    Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
    Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
    Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Mauricio D; Bellone S; Mutlu L; McNamara B; Manavella DD; Demirkiran C; Verzosa MSZ; Buza N; Hui P; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Mar; 170():38-45. PubMed ID: 36610380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
    Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
    Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
    Barok M; Tanner M; Köninki K; Isola J
    Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
    Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
    Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.
    Hayashi T; Seiler R; Oo HZ; Jäger W; Moskalev I; Awrey S; Dejima T; Todenhöfer T; Li N; Fazli L; Matsubara A; Black PC
    J Urol; 2015 Oct; 194(4):1120-31. PubMed ID: 26047983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
    Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
    Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.